XML 48 R38.htm IDEA: XBRL DOCUMENT v3.19.1

Revenue (Disaggregation of Revenue by Product) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue	$ 5,092.2	$ 4,963.8
U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,890.8	2,795.6
Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,201.4	2,168.2
Endocrinology
Disaggregation of Revenue [Line Items]
Revenue	2,930.1	2,698.7
Endocrinology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,873.9	1,715.9
Endocrinology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,056.2	982.9
Trulicity®
Disaggregation of Revenue [Line Items]
Revenue	879.7	678.3
Trulicity® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	665.6	528.2
Trulicity® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	214.1	150.1
Humalog®
Disaggregation of Revenue [Line Items]
Revenue	730.8	791.7
Humalog® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	448.6	504.1
Humalog® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	282.2	287.6
Forteo®
Disaggregation of Revenue [Line Items]
Revenue	312.9	313.2
Forteo® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	125.9	122.1
Forteo® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	187.0	191.1
Humulin®
Disaggregation of Revenue [Line Items]
Revenue	297.7	325.9
Humulin® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	201.3	221.6
Humulin® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	96.4	104.3
Basaglar®
Disaggregation of Revenue [Line Items]
Revenue	251.4	166.0
Basaglar® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	198.2	126.7
Basaglar® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	53.2	39.3
Jardiance
Disaggregation of Revenue [Line Items]
Revenue	203.6	151.0
Jardiance | U.S.
Disaggregation of Revenue [Line Items]
Revenue	125.2	95.0
Jardiance | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	78.4	56.0
Trajenta
Disaggregation of Revenue [Line Items]
Revenue	131.9	141.1
Trajenta | U.S.
Disaggregation of Revenue [Line Items]
Revenue	47.4	54.1
Trajenta | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	84.6	87.0
Other Endocrinology
Disaggregation of Revenue [Line Items]
Revenue	122.1	131.5
Other Endocrinology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	61.7	64.1
Other Endocrinology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	60.3	67.5
Oncology
Disaggregation of Revenue [Line Items]
Revenue	1,012.7	956.6
Oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	593.9	510.2
Oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	418.9	446.3
Alimta®
Disaggregation of Revenue [Line Items]
Revenue	499.2	499.6
Alimta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	281.8	245.3
Alimta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	217.4	254.3
Cyramza®
Disaggregation of Revenue [Line Items]
Revenue	198.3	183.6
Cyramza® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	75.1	68.3
Cyramza® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	123.2	115.3
Erbitux®
Disaggregation of Revenue [Line Items]
Revenue	118.4	149.6
Erbitux® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	113.3	121.3
Erbitux® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	5.1	28.3
Verzenio®
Disaggregation of Revenue [Line Items]
Revenue	109.4	29.7
Verzenio® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	93.5	29.7
Verzenio® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	15.9	0.0
Other Oncology
Disaggregation of Revenue [Line Items]
Revenue	87.4	94.1
Other Oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	30.2	45.6
Other Oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	57.3	48.4
Neuroscience
Disaggregation of Revenue [Line Items]
Revenue	393.1	472.7
Neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	51.1	91.2
Neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	342.0	381.5
Cymbalta®
Disaggregation of Revenue [Line Items]
Revenue	164.1	169.6
Cymbalta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	10.3	12.2
Cymbalta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	153.8	157.3
Zyprexa®
Disaggregation of Revenue [Line Items]
Revenue	107.2	122.6
Zyprexa® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	9.3	8.8
Zyprexa® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	97.9	113.8
Strattera®
Disaggregation of Revenue [Line Items]
Revenue	66.2	130.7
Strattera® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1.5	46.9
Strattera® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	64.7	83.7
Emgality®
Disaggregation of Revenue [Line Items]
Revenue	14.2	0.0
Emgality® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	12.2	0.0
Emgality® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	2.1	0.0
Other Neuroscience
Disaggregation of Revenue [Line Items]
Revenue	41.4	49.8
Other Neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	17.8	23.3
Other Neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	23.5	26.7
Immunology
Disaggregation of Revenue [Line Items]
Revenue	334.7	178.7
Immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	187.2	111.2
Immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	147.4	67.5
Taltz®
Disaggregation of Revenue [Line Items]
Revenue	252.5	146.5
Taltz® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	180.8	111.2
Taltz® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	71.7	35.3
Other Immunology
Disaggregation of Revenue [Line Items]
Revenue	82.2	32.2
Other Immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	6.4	0.0
Other Immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	75.7	32.2
Other
Disaggregation of Revenue [Line Items]
Revenue	421.6	657.1
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	184.7	367.1
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	236.9	290.0
Cialis®
Disaggregation of Revenue [Line Items]
Revenue	308.2	495.4
Cialis® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	143.2	313.4
Cialis® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	164.9	182.0
Other
Disaggregation of Revenue [Line Items]
Revenue	113.4	161.7
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	41.5	53.7
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	$ 72.0	$ 108.0

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=lly_InternationalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_EndocrinologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_TrulicityMemberMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_HumalogMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_ForteoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_HumulinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_BasaglarMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_JardianceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_TrajentaBIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_OtherEndocrinologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_OncologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_AlimtaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_CyramzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_ErbituxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_VerzenioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_OtherOncologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_NeuroscienceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_CymbaltaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_ZyprexaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_StratteraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_EmgalityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_ImmunologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_TaltzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_OtherImmunologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_OtherProductTotalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_CialisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_OtherProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: